SCHEMBL3376875

SCHEMBL3376875

CCOc1cc(C(F)(F)F)ccc1C(=O)NC(c1ccc(S(=O)(=O)Nc2nnc(C(F)(F)F)s2)cc1)C1CCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
P2RY1 P47900 1/20 0.40
AVPR2 P30518 1/20 0.39
GPR27 Q9NS67 1/20 0.39
USP2 O75604 1/20 0.39
USP8 P40818 1/20 0.39
SCN9A Q15858 2/20 0.38
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
POLB P06746 1/20 0.38
SCN5A Q14524 1/20 0.38
PDE2A O00408 4/20 0.38
KCNA5 P22460 2/20 0.37
SCN8A Q9UQD0 1/20 0.36
SCN10A Q9Y5Y9 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3373800 0.91 ALDH1A1 (0.42) MEN1KMT2AP2RY1AVPR2GPR27
SCHEMBL3376077 0.91 ALDH1A1 (0.42) MEN1KMT2AP2RY1AVPR2GPR27
SCHEMBL3376473 0.90 ALDH1A1 (0.42) MEN1KMT2AP2RY1AVPR2GPR27
SCHEMBL3777258 0.80 MEN1 (0.46) MEN1KMT2AP2RY1AVPR2GPR27
SCHEMBL1970190 0.80 SCN9A (0.40) MEN1KMT2AP2RY1AVPR2GPR27
SCHEMBL13068788 0.80 MEN1 (0.41) MEN1KMT2AP2RY1AVPR2GPR27
SCHEMBL3777973 0.80 ALDH1A1 (0.46) MEN1KMT2AP2RY1AVPR2GPR27
SCHEMBL3376873 0.79 P2RX7 (0.42) MEN1KMT2AP2RY1AVPR2GPR27
SCHEMBL3786565 0.75 ALDH1A1 (0.46) MEN1KMT2AP2RY1AVPR2GPR27
SCHEMBL3779306 0.75 ALDH1A1 (0.46) MEN1KMT2AP2RY1AVPR2GPR27

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937659-B1 CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS (FR) 2010-11-10 EP disclosed
US-7683181-B2 Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof SANOFI-AVENTIS (FR) 2010-03-23 US disclosed
US-20080280959-A1 CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2008-11-13 US disclosed
EP-1937659-A1 CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-07-02 EP disclosed
WO-2007039173-A1 CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280959-A1 CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF PPARD, GPR119, PPARG MEN1 4660/4885KMT2A 3679/4885P2RY1 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.